Want to see CVM full AI Analyst Report?
Top Page
Cel-Sci
(CVM)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▲(35.14% Upside)
Action:Reiterated
Date:10/01/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses, continued cash burn, and notable balance sheet volatility in TTM). Technicals provide some support due to short-term uptrend and positive MACD, but overbought momentum indicators and a price below the 200-day average temper the outlook. Valuation contributes limited support given the negative P/E and no dividend yield.
Positive Factors
CDMO Revenue Platform
The CDMO platform gives Cel-Sci a potential service-based revenue stream beyond its investigational therapy. Customer contracts and facility access could provide commercial diversification and operational infrastructure that remain useful even while product development continues.
Negative Factors
No Demonstrated Revenue
Zero reported revenue confirms that Cel-Sci remains pre-commercial and has not established a sales base for its operations. Without product revenue, the company depends on development progress and non-product sources to support future commercialization and scalability.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO Revenue Platform
The CDMO platform gives Cel-Sci a potential service-based revenue stream beyond its investigational therapy. Customer contracts and facility access could provide commercial diversification and operational infrastructure that remain useful even while product development continues.
Read all positive factors
Cel-Sci (CVM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.48M
Dividend YieldN/A
Average Volume (3M)117.13K
Price to Earnings (P/E)―
Beta (1Y)2.31
Revenue GrowthN/A
EPS Growth73.69%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume109,553
30 Day Avg. Volume117,130
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-2.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$18.98M
Cel-Sci Business Overview & Revenue Model
Company Description
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for th...
How the Company Makes Money
Cel-Sci’s revenue generation has historically been limited because it is primarily a development-stage biotechnology company and its lead therapeutic candidate, Multikine, has been investigational (i.e., not broadly marketed as an approved product...
Cel-Sci Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
34
Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.54M | -15.89M | -3.97M | -22.47M | 0.00 | 0.00 |
| EBITDA | -18.49M | -20.88M | -22.21M | -29.32M | -31.79M | -32.98M |
| Net Income | -22.70M | -25.41M | -26.92M | -32.37M | -36.70M | -36.36M |
Balance Sheet | ||||||
| Total Assets | 21.36M | 28.16M | 26.99M | 30.53M | 50.52M | 75.87M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 10.95M | 4.74M | 4.15M | 22.67M | 42.21M |
| Total Debt | 7.89M | 9.38M | 11.62M | 13.57M | 15.30M | 15.97M |
| Total Liabilities | 10.40M | 12.20M | 14.12M | 17.31M | 18.36M | 19.34M |
| Stockholders Equity | 10.96M | 15.96M | 12.87M | 13.21M | 32.16M | 56.53M |
Cash Flow | ||||||
| Free Cash Flow | -16.75M | -17.16M | -18.91M | -23.22M | -18.88M | -27.83M |
| Operating Cash Flow | -16.75M | -17.12M | -18.81M | -22.85M | -18.24M | -18.79M |
| Investing Cash Flow | -5.16K | -38.11K | -108.09K | -372.26K | 5.49M | -15.18M |
| Financing Cash Flow | 21.49M | 23.37M | 19.51M | 4.69M | -638.43K | 54.52M |
Cel-Sci Technical Analysis
Positive
1.48
Price Trends
1.53
Positive
1.40
Positive
2.88
Negative
Market Momentum
0.11
Negative
76.52
Negative
87.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVM, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 1.66, below the 50-day MA of 1.53, and below the 200-day MA of 2.88, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 76.52 is Negative, neither overbought nor oversold. The STOCH value of 87.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVM.
Cel-Sci Risk Analysis
Cel-Sci disclosed 39 risk factors in its most recent earnings report. Cel-Sci reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cel-Sci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $31.48M | -0.80 | -202.14% | ― | ― | 73.69% | |
47 Neutral | $66.88M | -0.72 | -53.22% | ― | ― | 55.84% | |
46 Neutral | $126.74M | -2.80 | -88.81% | ― | ― | 43.63% | |
44 Neutral | $63.64M | -3.62 | -48.25% | ― | ― | 96.65% |
* Healthcare Sector Average
CVM
Cel-Sci
2.06
-8.10
-79.72%
ATHE
Alterity Therapeutics
3.65
-0.54
-12.89%
XBIT
XBiotech
2.19
-0.45
-17.05%
PLRX
Pliant Therapeutics
1.08
-0.42
-28.00%
UNCY
Unicycive Therapeutics
4.70
0.08
1.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.